Immunyx
Immunyx is a drug development company focused on neutrophil modulation in disease, pioneering new approaches to immune modulation using novel pharmacological methods to modulate the toxic function of neutrophils in chronic diseases. The company aims to develop effective and safe treatments for diseases involving deregulated neutrophil damage, targeting large markets such as COPD, cancer, colitis, and arthritis.
Industries
Nr. of Employees
small (1-50)
Patents
Products
IMYX-3 (IBD & COPD programs)
Preclinical drug development programs aimed at modulating neutrophil toxicity for inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD); pipeline includes target validation, in vivo proof-of-concept, lead selection and planning toward pre-IND.
IMYX-5 (Oncology program)
Preclinical program focused on modifying neutrophil function in cancer to influence tumor immune microenvironment and therapeutic outcomes.
IMYX-LNP mRNA program
Orphan-designated program exploring neutrophil genomic manipulation using mRNA encapsulated in lipid nanoparticles.
IMYX-3 (IBD & COPD programs)
Preclinical drug development programs aimed at modulating neutrophil toxicity for inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD); pipeline includes target validation, in vivo proof-of-concept, lead selection and planning toward pre-IND.
IMYX-5 (Oncology program)
Preclinical program focused on modifying neutrophil function in cancer to influence tumor immune microenvironment and therapeutic outcomes.
IMYX-LNP mRNA program
Orphan-designated program exploring neutrophil genomic manipulation using mRNA encapsulated in lipid nanoparticles.
Services
Co-development and integration of external drug candidates into targeted nanoparticle formulations to improve delivery and safety profiles.
Co-development and integration of external drug candidates into targeted nanoparticle formulations to improve delivery and safety profiles.
Expertise Areas
- Neutrophil biology and modulation
- Targeted nanoparticle delivery
- mRNA LNP therapeutic development
- Preclinical in vivo models and translational research
Key Technologies
- Targeted nanoparticles
- Lipid nanoparticles (LNP) for mRNA delivery
- Liposome and polymer-based drug carriers
- Small-molecule modulators
News & Updates
We are thrilled to be announced as one of the awardees for the #BLUEKNIGHT #QuickFireChallenge. Inspired to continue innovating for a better and safer future. Thank you to our project partners at Akagera Medicines, Inc and the great team at VLX Ventures who continues to support our vision.
Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil functions can impact various diseases.
The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation announced Immunyx as a recipient of the Quick Fire Challenge.
Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected as a BlueKnight Company.
We are thrilled to be announced as one of the awardees for the #BLUEKNIGHT #QuickFireChallenge. Inspired to continue innovating for a better and safer future. Thank you to our project partners at Akagera Medicines, Inc and the great team at VLX Ventures who continues to support our vision.
Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil functions can impact various diseases.
The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation announced Immunyx as a recipient of the Quick Fire Challenge.
Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected as a BlueKnight Company.